Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA
Zantac sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible NDMA contamination of pills that had not yet been consumed.
New Delhi: The U.S. Food and Drug Administration said on Friday that tests it ran to simulate what happens to the commonly used heartburn drug Zantac in users' stomachs suggest it does not cause cancer-causing chemicals to form.
The regulator said it still plans to test the drugs in human patients to fully understand whether it causes levels of the probable carcinogen N-nitrosodimethylamine (NDMA) to form in patients.
Read Also: No carcinogen found in alternatives of heartburn drug Zantac, generics: USFDA
Zantac sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible NDMA contamination of pills that had not yet been consumed. The FDA said in October it found unacceptable levels of NDMA in drugs containing ranitidine.
Read Also: Sanofi pulls popular heartburn drug Zantac in the US, Canada
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd